ArticlePloS one2021
Evaluation of availability, price, and affordability of cardiovascular, diabetes, and global medicines in Abuja, Nigeria.
Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- The availability, cost, and affordability of essential medicines for asthma and COPD in low-income and middle-income countries: a systematic review.The Lancet. Global health · 2022Pooled it
- Trial
- Exploring factors affecting access to non-communicable disease medicines in low- and middle-income countries: a systematic review.BMJ public health · 2026Article
- Availability of essential medicines for non-communicable diseases: a scoping review of challenges and opportunities.BMJ global health · 2025Article
- Midodrine plus propranolol: potential problems and controversies behind remarkable efficacy.Hepatology international · 2025Article
- Managing medicines in decentralization: discrepancies between national policies and local practices in primary healthcare settings in Indonesia.Health policy and planning · 2025Article
- Access to essential medicines for noncommunicable diseases during conflicts: The case cardiovascular diseases, diabetes and epilepsy in Northern Syria.PLOS global public health · 2025Article
- Pakistan's first medicine price deregulation policy: assessing its impact on prices, affordability, and availability of oral anti-diabetic medicines in private pharmacies.Frontiers in pharmacology · 2025Article
- Prices of Anti-Diabetic Drugs Sold in Private Pharmacies in Côte d'Ivoire, 2023: A Secondary Analysis.ClinicoEconomics and outcomes research : CEOR · 2025Article
- Availability and affordability of antidiabetic medicines in Herat of Afghanistan in 2023.Journal of diabetes and metabolic disorders · 2024Article
- Availability and Price Variations of Commonly Used Cardiovascular Medicines at Community and Hospital Pharmacies in Gondar Town, Northwest Ethiopia.BioMed research international · 2024Article
- Assessment of prices, availability and affordability of essential medicines in Juba County, South Sudan.Journal of pharmaceutical policy and practice · 2023Article
- Economic burden of non-communicable diseases on households in Nigeria: evidence from the Nigeria living standard survey 2018-19.BMC public health · 2023Article
- Antihypertensive medicine use differs between Ghana and Nigeria.BMC cardiovascular disorders · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess the availability, price, and affordability of cardiovascular, diabetes, and global medicines in Abuja, Nigeria.
methodsA cross-sectional survey involving 27 private pharmacies, 13 public pharmacies, and 25 private hospital pharmacies in Abuja was conducted using the standardized World Health Organization/Health Action International methodology. The availability percentage for each pharmacy sector and each medicine was analyzed. The median price ratio (MPR) (ratio of the median price to the international reference prices) of the medicines were evaluated accordingly. Affordability was assessed by calculating the number of days' wages the lowest-paid unskilled government worker required to purchase a month worth of the standard treatment for a chronic condition.
resultsThe availability of cardiovascular (CV) medicines ranged from 28.4% (in private hospital pharmacies) to 59.9% (in private pharmacies). There was mixed variability in the mean availability of Originator Brands (OBs) and Lowest Priced Generics (LPGs) anti-diabetic drugs with the highest availability being OBs 36% and LPGs 40.2%, in private pharmacies and public pharmacies, respectively. The availability of global drugs ranged from 49.7% in private hospitals to 68.8% in private pharmacies. Two cardiovascular and four global medicines had greater than 80% availability across the pharmaceutical sectors. The median price ratio for OBs and LPGs was 9.60 and 1.72 for procurement, it was 8.08 and 2.60 in private pharmacies, 13.56 and 2.66 in public hospitals, and 16.38 and 7.89 in private hospitals. The percentage markup on LPG was 49.4% in public hospitals, 51.4% in private pharmacies, and 323% in private hospitals. Only nine medicines in both public hospitals and private pharmacies and two in the private hospital pharmacies required less than the daily wage of the lowest-paid government worker.
conclusionThe availability of cardiovascular, diabetes, and global medicines was below 80% across the different pharmaceutical sectors in Abuja and the medicines were unaffordable. Although the prices were generally exorbitant, private pharmacies offered the best options in terms of availability, pricing, and affordability of medicines. Therefore, the results of this study emphasize the pertinence of enforcing policies that facilitate the availability, pricing, and affordability of cardiovascular, diabetes, and global medicines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.